Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01937559 · ClinicalTrials.gov registry record · Phase 4
Topical Tranexamic Acid (TXA) in Joint Arthroplasty
A Phase 4 study, sponsored by The Hawkins Foundation.
- Completed
- Registry status
- Phase 4
- Development phase
- 188
- Enrollment target
NCT01937559: Completed Phase 4 study, sponsored by The Hawkins Foundation.
NCT01937559 is a Phase 4 study that has completed, run by The Hawkins Foundation. The registered enrollment target is 188 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (64% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01937559, a Phase 4 study, has completed, sponsored by The Hawkins Foundation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 188 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the efficacy of topical tranexamic acid (TXA) in decreasing blood loss following both shoulder arthroplasty and primary total hip arthroplasty. TXA functions to decrease blood loss by affecting the blood clotting system within the body. The investigators hypothesize that topical application of TXA prior to closure reduces postoperative bleeding as measured by absolute changes in postoperative hemoglobin levels and surgical drain output. In addition, use of topically applied tranexamic acid may reduce the need for transfusions, the rates of hematomas, infections, and length of hospital stay.
Primary Outcome
Blood loss will be calculated as the difference between the preoperative hemoglobin and the lowest postoperative hemoglobin during the hospital stay or the lowest postoperative hemoglobin prior to blood transfusion.
Interventions
- DRUG Normal saline
- BIOLOGICAL Tranexamic acid (TXA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2013-04 |
| Est. Completion | 2018-11 |
| Phase | Phase 4 |
What the finished NCT01937559 record still lists
NCT01937559 is an interventional study that assigns participants to a tested intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (64% lower).
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT01937559 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01937559 about?
NCT01937559 is a clinical study titled "Topical Tranexamic Acid (TXA) in Joint Arthroplasty". The objective of this study is to evaluate the efficacy of topical tranexamic acid (TXA) in decreasing blood loss following both shoulder arthroplasty and primary total hip arthroplasty. TXA functions to decrease blood loss by affecting the blood clotting system within the body. The investigators hy...
What is the current status of trial NCT01937559?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 188 participants. The study started on 2013-04. Estimated completion is 2018-11.
What interventions are being tested in trial NCT01937559?
The interventions under investigation include: Normal saline (DRUG), Tranexamic acid (TXA) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01937559?
This trial is sponsored by The Hawkins Foundation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01937559's enrollment target sits among peer trials
188 456th of 2000 higher than 1,542 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia